Anti-MYOZAP MYZAP Antibody

MYOZAP, also known as GRINL1A, is a 54 kDa highly conserved cardiac protein. It is strongly expressed in the heart and lung and is a novel component of intercalated disc. MYOZAP interacts with myosin phosphatase-RhoA interacting protein (MRIP) and acts as an activator of Rho-dependent SRF signaling. Knockdown study in zebrafish results in cardiomyopathy with severe dysfunction. The MYOZAP gene is part of a complex transcript unit that includes the gene for glutamate receptor, ionotropic, N-methyl D-aspartate-like 1A (GRINL1A) . Transcription of this gene occurs at an upstream promoter, with two different groups of alternatively spliced variants: Gup for GRINL1A upstream transcripts and Gcom for GRINL1A combined transcripts.

MYOZAP antibody was raised against a 18 amino acid synthetic peptide near the carboxy terminus of human MYOZAP. The immunogen is located within amino acids 400 - 450 of MYOZAP.

Plays a role in cellular signaling via Rho-related GTP- binding proteins and subsequent activation of transcription factor SRF (By similarity) . Targets TJP1 to cell junctions. In cortical neurons, may play a role in glutaminergic signal transduction through interaction with the NMDA receptor subunit GRIN1 (By similarity) . .

MYOZAP antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.